1
Pabnt Report This section provides information on worldwide patents relevant to vaccine design and production. The Patent Report gives the following information : title of patent, patentee, patent number, publication date and summary of the patent. A number of patents in this report are reproduced from 'Biotechnology Abstracts' with permission of Derwent Publications Ltd. Rochdale House, 128 Theobalds Road, London WC1X 8RP, Telephone 071 242 5823; Fax 071 405 3630. Bovine respiratory syncytial virus genes; cattle respiratory- syncytial virus recombinant nucleocapsid protein, matrix protein, phosphoprotein, etc. may be used for diagnosis and recombinant vaccine production; DNA sequence Samal S World 9207 940; 14 May 1992 The following are claimed: i. a DNA sequence which encodes a protein of cattle respiratory syncytial virus (CRSV) or a fragment comprising 15 or more bases, where the sequence is selected from the nucleocapsid protein gene, the matrix protein gene, the phosphoprotein gene, the small hydrophobic protein gene, the fusion protein gene, the glycoprotein gene and the M2 protein gene; ii. a replicative cloning vector comprising a DNA sequence as in (i.) and a replicon operative in a host cell; iii. an expression system comprising a DNA sequence as in (i.) operably linked to suitable control sequences; iv. a recombinant host cell e.g. Escherichia coli, transformed with an expression system as in (iii.); v. purified CRSV nucleocapsid protein, matrix protein, phosphoprotein, small hydrophobic protein, fusion protein, glycoprotein or M2 protein or fragments of these having the amino acid sequences specified; and vi. antibodies to each of the CRSV proteins as in (v.). The CRSV gene is derived from CRSV strain A51908 (ATCC VR-794) and strain FS-1. The CRSV proteins can be used to detect CRSV antibodies and as vaccines to prevent infection. 001-93 RNA molecule derived from alpha virus RNA genome; in vitro transcription vector, helper vector, and expression vector for recombinant vaccine production in animal cell culture Bioption World 9210 578 ; 25 June 1992 A new RNA sequence is capable of efficient infection of animal host cells, and contains complete alpha virus (AV) RNA genome regions essential for replication, and a target RNA inserted in a non-essential region. The following are also new : an RNA expression vector containing the new RNA packaged into infectious particles with a nucleocapsid, membrane and spike proteins; a DNA transcription vector containing cDNA complementary to the RNA; a DNA expression vector containing the cDNA immediately downstream of a phage SP6 RNA-polymerase promoter, and with defined 5' and 3' termini ; an RNA transcript from a target DNA in this vector; production of the vector from a defective vector and helper RNA; a helper virus with packaging sequences; an animal cell culture transformed with the RNA, the DNA transcription vector, or the recombinant expression vector; production of a recombinant protein in animal cells using the vectors or in vitro transcription; an antigen comprising a chimeric alpha virus with an exogenous epitope or antigen inserted in its structural proteins; and a recombinant vaccine containing the antigen. 002-93 Assembled viral particles useful as a rotaviral vaccine; rotavirus recombinant inner capsid protein VP6, outer capsid protein VP4, VP7 particle assembly for potential recombinant vaccine production; DNA sequence Univ. Saskatchewan World 9207 941; 14 May 1992 The following are claimed : i. a viral particle assembly capable of eliciting an immunological response in a vertebrate comprising an inner capsid protein homologous and functionally equivalent to VP6, and one or more outer capsid proteins which are a protein homologous and functionally equivalent to VP4 or a fragment of this, and/or a protein homologous and functionally equivalent to VP7; ii. a viral particle assembly capable of eliciting an immunological response in a vertebrate subject comprising VP6 assembles with V4 and VP7; iii. a vaccine composition comprising a carrier and the viral particle assembly of (i.) or (ii.); and iv. treatment or prevention of rotaviral disease in a vertebrate by administering the vaccine. The proteins of (i.) and (ii.) are produced using recombinant techniques. The vaccine compositions further comprise one or more unassembled proteins from VP6, VP4 and VP7. The unassembled protein is provided in a cell lysate. The vaccine also contains an adjuvant. The vaccines are useful in preventing and ameliorating rotaviral infection, which causes gastro- intestinal disorders and diarrhoea. 003-93 Sperm cell surface protein PH-20 and DNA encoding it; contraceptive recombinant vaccine production Univ. Connecticut World 9210 569 ; 25 June 1992 A new DNA sequence encoding all or part of a surface protein (SP), present in the sperm of a mammal, is new. The SP is essential for fertilization in the mammal, and is preferably a human PH-20 sperm SP. The following are also new: an expression vector containing the DNA; a method for production of recombinant PH-20 protein by transforming a cell with the vector; the recombinant PH-20 protein; a contraceptive method for a non-guinea-pig mammal (e.g. human, cattle, dog or cat) by active immunization with an SP essential for fertilization of the same species; and a contraceptive vaccine containing the SP. The DNA sequence and protein sequence for the human PH-20 SP are provided in the specification. The new contraceptive vaccine is longer-lasting than the oral contraceptive pill, but is not a permanent form of contraception like surgical sterilization. The new method is as effective as or more effective than other methods. In an example, PH-20 DNA was isolated from a human testis gene bank in phage lambda-gtll, by screening with mouse and guinea-pig PH-20 cDNA probes. Positive cDNA clones H18 and H16 were isolated and sequenced. 004-93 0264-410)(/93/010091-02 © 1993 Butterworth-Heinemann Ltd Vaccine, Vol. 11, Issue 1, 1993 91

Assembled viral particles useful as a rotaviral vaccine; rotavirus recombinant inner capsid protein VP6, outer capsid protein VP4, VP7 particle assembly for potential recombinant vaccine

  • View
    212

  • Download
    0

Embed Size (px)

Citation preview

Pabnt Report This section provides information on worldwide patents relevant to vaccine design and production. The Patent Report gives the following information : title of patent, patentee, patent number, publication date and summary of the patent. A number of patents in this report are reproduced from 'Biotechnology Abstracts' with permission of Derwent Publications Ltd. Rochdale House, 128 Theobalds Road, London WC1X 8RP, Telephone 071 242 5823; Fax 071 405 3630.

Bovine respiratory syncytial virus genes; cattle respiratory- syncytial virus recombinant nucleocapsid protein, matrix protein, phosphoprotein, etc. may be used for diagnosis and recombinant vaccine production; D N A sequence Samal S World 9207 940; 14 May 1992

The following are claimed: i. a DNA sequence which encodes a protein of cattle respiratory syncytial virus (CRSV) or a fragment comprising 15 or more bases, where the sequence is selected from the nucleocapsid protein gene, the matrix protein gene, the phosphoprotein gene, the small hydrophobic protein gene, the fusion protein gene, the glycoprotein gene and the M2 protein gene; ii. a replicative cloning vector comprising a DNA sequence as in (i.) and a replicon operative in a host cell; iii. an expression system comprising a DNA sequence as in (i.) operably linked to suitable control sequences; iv. a recombinant host cell e.g. Escherichia coli, transformed with an expression system as in (iii.); v. purified CRSV nucleocapsid protein, matrix protein, phosphoprotein, small hydrophobic protein, fusion protein, glycoprotein or M2 protein or fragments of these having the amino acid sequences specified; and vi. antibodies to each of the CRSV proteins as in (v.). The CRSV gene is derived from CRSV strain A51908 (ATCC VR-794) and strain FS-1. The CRSV proteins can be used to detect CRSV antibodies and as vaccines to prevent infection.

001-93

RNA molecule derived from alpha virus RNA genome; in vitro transcription vector, helper vector, and expression vector for recombinant vaccine production in animal cell culture Bioption World 9210 578 ; 25 June 1992

A new RNA sequence is capable of efficient infection of animal host cells, and contains complete alpha virus (AV) RNA genome regions essential for replication, and a target RNA inserted in a non-essential region. The following are also new : an RNA expression vector containing the new RNA packaged into infectious particles with a nucleocapsid, membrane and spike proteins; a DNA transcription vector containing cDNA complementary to the RNA; a DNA expression vector containing the cDNA immediately downstream of a phage SP6 RNA-polymerase promoter, and with defined 5' and 3' termini ; an RNA transcript from a target DNA in this vector; production of the vector from a defective vector and helper RNA; a helper virus with packaging sequences; an animal cell culture transformed with the RNA, the DNA transcription vector, or the recombinant expression vector; production of a

recombinant protein in animal cells using the vectors or in vitro transcription; an antigen comprising a chimeric alpha virus with an exogenous epitope or antigen inserted in its structural proteins; and a recombinant vaccine containing the antigen.

002-93

Assembled viral particles useful as a rotaviral vaccine; rotavirus recombinant inner capsid protein VP6, outer capsid protein VP4, VP7 particle assembly for potential recombinant vaccine production; D N A sequence Univ. Saskatchewan World 9207 941; 14 May 1992

The following are claimed : i. a viral particle assembly capable of eliciting an immunological response in a vertebrate comprising an inner capsid protein homologous and functionally equivalent to VP6, and one or more outer capsid proteins which are a protein homologous and functionally equivalent to VP4 or a fragment of this, and/or a protein homologous and functionally equivalent to VP7; ii. a viral particle assembly capable of eliciting an immunological response in a vertebrate subject comprising VP6 assembles with V4 and VP7; iii. a vaccine composition comprising a carrier and the viral particle assembly of (i.) or (ii.); and iv. treatment or prevention of rotaviral disease in a vertebrate by administering the vaccine. The proteins of (i.) and (ii.) are produced using recombinant techniques. The vaccine compositions further comprise one or more unassembled proteins from VP6, VP4 and VP7. The unassembled protein is provided in a cell lysate. The vaccine also contains an adjuvant. The vaccines are useful in preventing and ameliorating rotaviral infection, which causes gastro- intestinal disorders and diarrhoea.

003-93

Sperm cell surface protein PH-20 and D N A encoding it; contraceptive recombinant vaccine production Univ. Connecticut World 9210 569 ; 25 June 1992

A new DNA sequence encoding all or part of a surface protein (SP), present in the sperm of a mammal, is new. The SP is essential for fertilization in the mammal, and is preferably a human PH-20 sperm SP. The following are also new: an expression vector containing the DNA; a method for production of recombinant PH-20 protein by transforming a cell with the vector; the recombinant PH-20 protein; a contraceptive method for a non-guinea-pig mammal (e.g. human, cattle, dog or cat) by active immunization with an SP essential for fertilization of the same species; and a contraceptive vaccine containing the SP. The DNA sequence and protein sequence for the human PH-20 SP are provided in the specification. The new contraceptive vaccine is longer-lasting than the oral contraceptive pill, but is not a permanent form of contraception like surgical sterilization. The new method is as effective as or more effective than other methods. In an example, PH-20 DNA was isolated from a human testis gene bank in phage lambda-gtl l , by screening with mouse and guinea-pig PH-20 cDNA probes. Positive cDNA clones H18 and H16 were isolated and sequenced.

004-93

0264-410)(/93/010091-02 © 1993 Butterworth-Heinemann Ltd Vaccine, Vol. 11, Issue 1, 1993 91